Does taking capecitabine or trastuzumab emtansine treat triple-negative breast cancer effectively?

Triple-negative breast cancer (TNBC) is a subtype that lacks receptors for estrogen, progesterone, and HER2. Because TNBC cells do not have HER2 receptors, drugs that target HER2—like trastuzumab emtansine (T-DM1)—are not effective for TNBC. Capecitabine is a chemotherapy drug sometimes used in breast cancer, but it is not specifically approved or recommended as a standard treatment for TNBC. Current effective treatments for TNBC include chemotherapy combinations and immunotherapy.

What the research says

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate designed to target HER2-positive breast cancer cells. Since TNBC is defined by the absence of HER2 expression, T-DM1 has no target in TNBC and is not used for this subtype ¹. Capecitabine is an oral chemotherapy used in some breast cancers, but it is not a standard treatment for TNBC. Reviews of chemotherapy for breast cancer note that TNBC is typically treated with anthracyclines, taxanes, platinum agents, and immune checkpoint inhibitors, not capecitabine ¹². Studies show that adding immunotherapy (such as PD-1/PD-L1 inhibitors) to chemotherapy improves outcomes in TNBC, but capecitabine is not part of these standard regimens ⁵⁷. In a meta-analysis, combining immune checkpoint inhibitors with chemotherapy improved pathological complete response and event-free survival in TNBC, but the chemotherapy backbones used were not capecitabine ⁷. Therefore, neither capecitabine nor trastuzumab emtansine is considered effective for treating TNBC.

What to ask your doctor

• What are the standard chemotherapy options for my type of triple-negative breast cancer?
• Would immunotherapy (such as a PD-1 or PD-L1 inhibitor) be appropriate for my case?
• Are there any clinical trials available for new treatments for TNBC?
• Should I be tested for BRCA mutations, which might open up other treatment options like PARP inhibitors?